Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16385280 | 0.84 | PTGS2 (0.49) | MAPTKDM4EALDH1A1MKNK1MKNK2 | |
| SCHEMBL8184854 | 0.75 | MAPT (0.58) | MAPTKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL12326165 | 0.74 | MAPT (0.56) | MAPTKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL29697785 | 0.74 | MAPT (0.56) | MAPTKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL8390535 | 0.74 | MAPT (0.48) | MAPTKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15730178 | 0.74 | CYP11B2 (0.56) | NPC1RAB9APTGS2 | |
| SCHEMBL8387066 | 0.74 | MAPT (0.48) | MAPTKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4095298 | 0.74 | CLK4 (0.58) | KDM4EALDH1A1HPGDMKNK1MKNK2 | |
| SCHEMBL17877755 | 0.74 | MAPT (0.48) | MAPTKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL16432929 | 0.73 | EGFR (0.37) | MKNK1MKNK2PDE2APDE10APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027619-B1 | BICYCLIC UREAS AND THIADIAZOLIDINE-1,1-DIOXIDES AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-3027619-B1 | BICYCLIC UREAS AND THIADIAZOLIDINE-1,1-DIOXIDES AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-02 | — | — | EP | disclosed |
| US-9981970-B2 | Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981970-B2 | Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160185784-A1 | BICYCLIC UREAS AND THIADIAZOLIDINE-1, 1-DIOXIDES AS CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2016-06-30 | — | — | US | disclosed |
| US-20160185784-A1 | BICYCLIC UREAS AND THIADIAZOLIDINE-1, 1-DIOXIDES AS CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2016-06-30 | — | — | US | disclosed |
| US-20160185784-A1 | BICYCLIC UREAS AND THIADIAZOLIDINE-1, 1-DIOXIDES AS CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2016-06-30 | — | — | US | disclosed |
| EP-3027619-A2 | BICYCLIC UREAS AND THIADIAZOLIDINE-1,1-DIOXIDES AS CETP INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017302-A2 | BICYCLIC UREAS AND THIADIAZOLIDINE-1,1-DIOXIDES AS CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015017302-A2 | BICYCLIC UREAS AND THIADIAZOLIDINE-1,1-DIOXIDES AS CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185784-A1 | BICYCLIC UREAS AND THIADIAZOLIDINE-1, 1-DIOXIDES AS CETP INHIBITORS | CETP, CES1, PON1 | MAPT 1903/4885KDM4E 2206/4885SMN1; SMN2 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.